 The FDA has approved Nyxoah SAs NASDAQ: NYXH Investigational Device Exemption IDE to initiate a trial, called ACCCESS, to evaluate the Genio system for moderate-to-severe Obstructive Sleep Apnea OSA and Complete Concentric Collapse CCC of the soft palate. The FDA. 